DMPK and Tox studies

We provide an extensive and adaptable selection of in vitro DMPK studies and in vivo DMPK studies that cover a broad range of activities from hit-to-lead and lead optimization phases to candidate selection, and subsequently perform studies to support up to IND filing within integrated drug discovery and CRDMO services.

Understanding the intricacies of how compounds interact with biological systems is at the heart of developing therapies that are not only effective but also safe. Our DMPK and toxicology studies are meticulously designed to navigate the complex landscape of drug metabolism, pharmacokinetics, and safety assessment, ensuring your drug candidates are optimized for success from the early stages of drug discovery services to the final steps before clinical trials.

Highlights

Fast turnaround times for in vitro and in vivo studies.
Sciex 4500 QTrap eqSciex 4500 QTrap equipped with LightSight software for soft spot metabolite identification
Expert scientific interpretations that enable advancement of drug development programs.
Support for structure-activity relationship (SAR) modifications within integrated drug discovery programs.

In-Vitro ADME Studies

Our in vitro ADME services are pivotal for early-stage drug discovery, providing critical insights into the absorption, distribution, metabolism, and excretion (ADME) of compounds. We employ a suite of state-of-the-art technologies and methodologies, supporting advanced small molecule R&D, including:

Physicochemical Screening

Utilizing kinetic and thermodynamic methods, we assess solubility in biorelevant media (FaSGF, FaSSIF, FeSSIF) and PBS, alongside stability studies in fresh plasma, blood, and across various pH levels to strengthen drug discovery programs.

Permeability Assays

Through PAMPA, Caco-2, and MDCK-MDR1 assays, we evaluate the permeability of drug candidates to predict oral absorption and blood-brain barrier penetration, contributing to efficient preclinical development. .

Metabolism Studies

Our comprehensive metabolism assessments include metabolic stability in liver microsomes and hepatocytes, Met-ID studies, CYP inhibition and induction profiles, offering deep insights into the metabolic fate of compounds within pharmaceutical research and development.

In-Vivo Studies

The transition from in vitro assessments to in vivo studies is a critical step in drug development solutions. Our in vivo DMPK studies at LAXAI Life Sciences encompass:

Pharmacokinetics

We conduct comprehensive pharmacokinetics studies across a variety of animal models, including mice, rats, beagle dogs, rabbits, hamsters, and monkeys, to understand the absorption, distribution, metabolism, and elimination (ADME) of drug candidates, supporting advanced small molecule R&D and preclinical development.

Excretion Studies

Utilizing metabolic cages, we provide detailed analysis on the excretion patterns of compounds, aiding in the understanding of drug metabolism and clearance mechanisms within drug discovery programs.

Distribution Assessments

Our tissue distribution studies offer invaluable data on the localization and concentration of compounds within the body, ensuring targeted efficacy and minimized off-target effects in drug discovery services.

Safety Assessment

Safety is paramount in drug development. Our toxicology studies (TOX) at LAXAI Life Sciences are designed to identify potential toxicities early in the development process within a comprehensive CRDMO services framework.

Toxicology Testing

We conduct a broad range of toxicology testing services, including acute and chronic studies, to assess the safety profile of drug candidates and support pharmaceutical research and development.

ADME-Tox Integration

Our integrated ADME-Tox studies approach combines pharmacokinetics, toxicity, and genotoxicity assessments to ensure that compounds are both effective and safe for clinical use, reinforcing integrated drug discovery and drug development programs.